Photobiomodulation Research: This Week's Science - May 2026
Share
Published: 7 May 2026 | Source: PubMed alert, week beginning 4 May 2026 - fotobiomodulasjon research digest
Quick Answer: The standout paper this week is a randomised controlled trial from Korea showing that 12 weeks of home-based near-infrared photobiomodulation significantly improved cognitive scores in people with mild cognitive impairment linked to Alzheimer's disease - with a mean MoCA improvement of nearly 4 points versus a decline in the placebo group. Separately, a clean RCT found that red light therapy measurably improved reading ability and eye comfort in people with presbyopia. Both used home devices.
Right, this week I am doing something a bit different. Instead of going broad, I want to walk you through what actually landed in my PubMed alert this week - papers published between 27 April and 4 May 2026 - and tell you honestly which ones matter and why.
There are 35 papers in this alert. Most of them are dental laser studies. Which, fine, laserbehandling (laser treatment) in dentistry is a legitimate and growing application of PBM - but unless you are a dentist, the details of whether 808 nm or 650 nm works better for post-implant pain relief is not going to change your Tuesday. So I have filtered those out and focused on the studies that speak to problems real people are actually living with.
This week those problems include Alzheimer's, ageing eyes, asthma, menopause symptoms, burn scars, and fracture recovery. Let's go.
Alzheimer's and Mild Cognitive Impairment - This Is the One to Read
I want to be careful with this section because I know how much is riding on anything that looks like hope for Alzheimer's. So let me be precise about what this study did and what it found.
A randomised, double-blind, placebo-controlled trial published in the Journal of Alzheimer's Disease (PMID 42024020) recruited 80 people who met the clinical criteria for mild cognitive impairment (MCI) due to Alzheimer's disease. These are people in the early stage, where cognition is measurably declining but they can still function independently. This is the window where intervention matters most.
Participants self-administered a home-based transcranial photobiomodulation device emitting 808 nm near-infrared light over both sides of the prefrontal cortex, six times a week for 12 weeks. The placebo group did the same sessions with an inactive device.
The primary outcome was change in the MoCA-K score - a standard cognitive assessment used in clinical practice worldwide. Active tPBM: mean improvement of 3.87 points. Placebo group: mean decline of 0.74 points. Between-group difference: statistically significant at p < 0.001.
Secondary measures of memory and cognition also improved significantly. Depression scores did not change. No adverse events. High adherence to home treatment.
To put the MoCA change in context: a 3-point improvement on this scale is clinically meaningful. The fact that the placebo group declined while the active group improved represents a meaningful separation in trajectory - not just symptom relief but a possible slowing of progression.
The limitations are real: 80 people is not a large trial, it is a Korean cohort, and 12 weeks is not long enough to know whether the benefit persists. The researchers themselves call this a "confirmatory trial" rather than a definitive one. What it does is build a case that is now hard to ignore. The mechanism - near-infrared light improving mitochondrial energy metabolism and cerebral blood flow in a brain where bioenergetic failure is increasingly understood as central to the disease process - is coherent.
If you have a parent or partner showing early cognitive decline, this is worth knowing about. The Therapy Hat and the 810nm MEGA Torch are the home devices in our range that sit closest to the transcranial near-infrared approach used here.
(Chun et al., Journal of Alzheimer's Disease, 2026, Read the study)
Reading Glasses Getting Stronger Every Year? There Is an RCT for That
This one surprised me. Not because I did not know red light was being studied for eye health - I have followed Prof. Glen Jeffery's work on this for years - but because the specific application here is presbyopia, which is something almost nobody talks about in the PBM world and yet affects essentially everyone over 45.
Presbyopia is what happens when the lens of your eye gradually loses its flexibility and you can no longer focus on close objects. Reading glasses. Menu-at-arm's-length. Phone held at full stretch. You know the drill. It is not a disease exactly - it is an almost universal consequence of ageing - but it significantly affects quality of life and there is currently no non-surgical treatment that reverses it.
A randomised, double-masked, placebo-controlled clinical trial published in Annals of Medicine (PMID 42046494) enrolled 64 adults aged 41-62 with presbyopia and self-reported eye strain. Participants were randomised to repeated low-level red light (RLRL) therapy or sham for one month.
At day 31, the red light group showed significant improvements in the computer vision syndrome questionnaire score (less eye strain) and binocular accommodative amplitude - meaning their eyes could actually focus over a wider range than before. The improvement in reading comfort was also significant. No adverse events. High adherence.
The mechanism connects to what we know about mitochondrial function in retinal and ciliary muscle cells - the same tissues that drive accommodation. They are among the most metabolically active in the body. When they are running low on energy, function degrades. Red light in the appropriate range supports their mitochondrial activity.
This is worth knowing about for everyone over 45, and absolutely for those of us in Norway where we spend months every year under artificial light with limited access to the natural red and near-infrared spectrum (nærinfrarødt lys) that these tissues evolved alongside. øyehelse (eye health) is not just about prescriptions - it is about whether your eyes are getting what they need to function well.
(Song et al., Annals of Medicine, 2026, Read the study)
PBM for Asthma - Not Where Most People Would Look
I genuinely did not have asthma on my PBM radar in the way this study framed it. Worth a section.
A randomised, triple-blind controlled trial published in Lasers in Medical Science (PMID 42059974) tested what happens when you add LED-based photobiomodulation to a resistance training programme in 30 adults with difficult-to-control asthma. Difficult-to-control asthma means persistent symptoms and frequent flare-ups despite full pharmacological treatment. These people are on multiple inhalers and still struggling.
Peripheral muscle weakness is a common and underappreciated feature of difficult asthma. It limits exercise capacity and makes rehabilitation harder. The study split participants into resistance training alone versus resistance training plus pre-session PBMT. Both groups trained twice weekly for 12 weeks.
The results: the PBM group showed significantly greater gains in muscle strength across major muscle groups, improved oxygen consumption at the anaerobic threshold, and better performance on the shuttle walk test. Pulmonary function (spirometry) and asthma control scores did not differ between groups.
That last part is important to understand. PBM did not directly improve lung function or asthma symptoms in this study. What it did was improve the muscles around the breathing effort - making the whole body more capable of handling physical stress. In a condition where fatigue and exercise intolerance are significant quality-of-life factors, that is clinically useful even if it is not a direct treatment for the underlying inflammation.
If you or someone in your family is dealing with asthma alongside general physical deconditioning or muscle weakness, this is a relevant finding. A red light panel used before exercise sessions is the practical home-use parallel.
(Costa et al., Lasers in Medical Science, 2026, Read the study)
Menopause and Urinary Incontinence - A Placebo-Controlled Trial
This is one that a lot of women will want to know about and that gets far too little attention.
Genitourinary syndrome of menopause (GSM) covers the range of genital, urinary, and sexual symptoms that come with estrogen decline - vaginal dryness, burning, urinary leakage, and reduced sexual comfort. Women spend roughly a third of their lives postmenopause. The available treatments are limited and not everyone can or wants to use hormones.
A randomised, double-blind, placebo-controlled clinical trial published in Climacteric (PMID 42060269) tested 808 nm laser photobiomodulation applied to eight vaginal points across four weekly sessions in postmenopausal women presenting with GSM symptoms. The placebo group followed the same protocol with the device off.
Results: significant reduction in urinary leakage in the PBM group, with improved scores on the standard urinary incontinence questionnaire. Vaginal dryness and burning also improved. Pelvic pressure and sexual function did not reach statistical significance in this study - smaller effects or possibly requiring longer treatment.
The mechanism is what you would expect: PBM stimulating collagen synthesis, improving tissue elasticity and vascularity in mucous membranes that have become atrophied due to estrogen withdrawal. The same mechanism that makes red light useful for skin rejuvenation applies to mucosal tissue.
We do stock a vaginal wand device specifically for this application - it is the same principle as the clinical protocol in this study, applied at home. The study used 808 nm, which is in the near-infrared range. This is one of the more niche but genuinely evidence-backed applications in the home-use space right now.
(Pereira et al., Climacteric, 2026, Read the study)
Burn Recovery - Getting Out of Hospital 33 Days Earlier
Severe burns are one of the more extreme wound healing challenges in medicine. Healing is slow, painful, incomplete, and significantly affects function and quality of life long after the acute phase.
A comparative clinical study published in Life (PMID 42073421) followed 65 patients with severe burns - 35 received standard care plus adjunctive MLS (Multiwave Locked System) laser therapy, 30 received standard care alone. The primary outcome was time to complete epithelialization - essentially when the wound closes over.
The results are striking. Median time to complete healing in the MLS laser group: 40 days. Standard care group: 73 days. That is a 33-day difference. A month. Of hospitalisation, wound care, pain, and risk of infection. The laser group also had significantly greater wound area reduction, better scar quality, less pain, and less pruritus.
The limitations are fair ones to note: this was not a randomised controlled trial but a comparative study with some retrospective elements, and 65 patients is not enormous. The researchers acknowledge this and call for RCTs. But a 33-day difference in healing time is not a marginal finding, and the direction of evidence across multiple secondary measures is consistent.
For anyone dealing with ongoing wound care in a clinical setting - burns, post-surgical wounds, or slow-healing injuries - the question of whether their treatment centre uses any form of photobiomodulation is worth asking. What Norwegian clinicians sometimes call lysbehandling (light treatment) in wound care contexts has a growing evidence base behind it.
(Postoiu et al., Life, 2026, Read the study)
Fractured Bones: PBM Helps in the Short Term
A systematic review and meta-analysis published in Annals of Medicine (PMID 42080480) pooled data from 12 studies on photobiomodulation for fracture pain and recovery. This is useful as a summary of where the evidence stands.
The finding: PBM significantly reduced pain at one week post-fracture compared to placebo, across different fracture locations and wavelength combinations. In upper limb fractures specifically, grip strength at four weeks was significantly greater in the PBM group than placebo. A meaningful practical result - if your wrist is fractured and you need to recover function for work, getting grip strength back faster matters.
What PBM did not do in this review: produce significant differences in pain or function at 4-26 weeks, or show consistent evidence for faster bone healing itself. So this is a short-term pain and early functional recovery benefit, not a long-term bone repair effect based on current evidence.
That is an honest and useful distinction. If you have had a fracture and are in the acute recovery phase, PBM appears to genuinely help with pain and initial function. If you are expecting it to speed up bone knitting over months, the current evidence is not there yet.
(Wang et al., Annals of Medicine, 2026, Read the study)
Scars - Red and Near-Infrared Light as a Non-Invasive Option
A scoping review published in Lasers in Medical Science (PMID 42026334) pulled together seven clinical studies covering 297 patients and looked at the evidence for red and near-infrared PBM in burn scars, hypertrophic scars, and post-surgical scars.
The finding across the studies: red LED improved scar scores, pigmentation, and thickness in both paediatric and adult burn scars, with greater benefits in scars under 12 months old. Post-surgical scars showed reduced hardness and better appearance scores. Near-infrared PBM reduced pain, pruritus, and thickness in hypertrophic scars following hernia repair, thyroidectomy, and eyelid surgery. Across all studies, PBM was well tolerated.
The clinical message: if you have a scar from surgery, a burn, or an injury, starting PBM treatment early - while the scar is still forming - appears to produce better results than starting later. This fits the known biology: light-driven modulation of collagen synthesis and inflammatory signalling is most impactful during the active remodelling phase.
If you or someone you know has had recent surgery or a significant burn, this is a practical application where a portable red light device or panel targeting the affected area from early in recovery has solid evidence behind it.
(Gaumond et al., Lasers in Medical Science, 2026, Read the study)
The Honest Picture
This week's alert was dominated by dental studies - not the most exciting reading for most people, though the laserbehandling work in dentistry is genuinely solid. What I have picked out above represents the human-relevant signal in an alert that had a lot of specialist noise.
A few things worth saying about the evidence quality this week. The Alzheimer's trial is the strongest paper in terms of design and significance of finding - 80 people, proper randomisation, blinding, a meaningful primary outcome, and a result that held across secondary measures. The presbyopia trial is clean and well-designed for its size. The asthma and menopause trials are smaller but properly randomised. The burn recovery study and fracture review are both honest about their limitations.
None of this is settled science in the sense that no one paper closes the question. But the pattern across applications - from cognitive decline to eye health to post-surgical recovery - keeps pointing in the same direction.
On devices: the Alzheimer's and cognitive studies consistently use near-infrared at 808-810 nm delivered to the skull. The 810nm MEGA Torch and Therapy Hat are the home-use devices in our range that sit closest to that approach. For wound healing, burn recovery, scar treatment, and musculoskeletal applications, the panels and portable wraps are the right tools.
Every device we sell is spectrometer-tested. In a market where claimed output and real output can be wildly different - I have returned units where the measured irradiance was a fraction of what was on the spec sheet - that is not a small thing.
A Note for Norway
Worth flagging specifically for those of us here: the mørketid deprivation of red and near-infrared wavelengths is real and long. October through March at 58-60 degrees north, you are simply not getting meaningful photobiomodulation from natural light. The conditions that drive the applications covered above - mitochondrial underperformance in neural tissue, reduced collagen turnover, impaired cellular energy production - are all worse when you have spent months without access to the light spectrum that addresses them.
The presbyopia finding is particularly relevant for Norwegian office workers spending long winters under fluorescent or LED lighting with no natural red spectrum exposure. øyehelse does not get better on its own. The cognitive ageing research is relevant for an ageing population dealing with the specific metabolic challenges of long dark winters.
FAQ
What is photobiomodulation (fotobiomodulasjon) and how does it work? It uses specific wavelengths of red and near-infrared light (nærinfrarødt lys) to stimulate cellular energy production - primarily through cytochrome c oxidase inside the mitochondria. When the right wavelengths hit the right tissue, cells produce more energy, repair processes accelerate, and inflammation is modulated. Think of it as switching cells back on that have been running at low power.
Can red light therapy really help with Alzheimer's at home? The trial published this week showed significant cognitive improvement over 12 weeks using a home-based 808 nm device applied to the forehead. It is a confirmatory trial, not a definitive one - but 80 people, proper blinding, and a meaningful separation between active and placebo groups is genuinely encouraging. The mechanism is coherent: near-infrared light supporting mitochondrial function in a brain where energy metabolism is failing. If someone in your family has MCI, this is worth discussing with their doctor alongside the research.
I am over 45 and my reading is getting worse. Is there actually evidence for red light helping that? Yes - this week's alert included a proper double-masked RCT showing significant improvement in accommodative amplitude and eye strain scores after one month of repeated low-level red light therapy. It is a 64-person study, so not enormous, but it is well-designed and the result was clear. The mechanism relates to mitochondrial support in the ciliary muscles of the eye that drive focus.
What is the best device for cognitive health and brain applications? Based on the clinical research, you want near-infrared at 808-810 nm delivered to the head - either transcranially (through the skull) or intranasally. The 810nm MEGA Torch is Norway's only dedicated 810 nm portable device running above 120 mW/cm2. The Therapy Hat covers the scalp. Get in touch before buying - the right protocol matters as much as the device.
What about for wound healing and scars? Both red (633-670 nm) and near-infrared (808-830 nm) have evidence for scar remodelling and wound healing. Earlier in the healing process is better. A panel or portable wrap targeted to the area works well for this application.
Is red light therapy safe? Across everything in this week's alert - multiple RCTs, comparative studies, and systematic reviews - no clinically significant adverse events were reported. Standard cautions apply: goggles for high-power panels near the eyes, and check with a doctor if you are taking photosensitising medications.
Browse the full range: red light panels for whole-body and musculoskeletal use, the 810nm MEGA Torch and portable devices for targeted neurological and specialist applications, and the Therapy Hat for dedicated brain and scalp stimulation. All priced in NOK with Vipps and Klarna at checkout.
Disclaimer: This post is for educational and informational purposes only. It is not medical advice. The studies discussed are peer-reviewed research; they are not claims about specific devices or products. If you have a medical condition, speak to a qualified healthcare provider before starting any new therapy.
[Meta description: Photobiomodulation research May 2026: Alzheimer's RCT, presbyopia, asthma, menopause and scar healing. What this week's PubMed alert actually found.]